文献速递肿瘤 PET/CT

基于PSMA PET/CT的局部分期对根治性前列腺切除术后生化复发的预后价值

Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-07-28

这项国际多中心回顾性研究分析了476例局限或局部进展期miN0前列腺癌患者,术前接受PSMA PET/CT和MRI分期后行机器人辅助根治性前列腺切除术(2016–2023)。多因素Cox回归显示PSMA PET T分期≥T3b与生化复发无生存(BRFS)独立相关(HR 2.75,95% CI 1.63–4.63),提示基于PSMA PET的局部分期可能改善风险分层。

要点

  • PSMA PET T分期≥T3b vs ≤T2的BRFS HR为2.75(95% CI 1.63–4.63)。
  • MRI与PSMA PET均诊断T3b者2年BRFS为19%,仅MRI诊断T3b者为58%(p=0.03)。
  • 127例生化复发中101例(79.5%)发生于术后两年内。

原文

PURPOSE: PSMA PET/CT outperforms conventional imaging for detecting pelvic nodal and distant metastasis, but its role regarding local staging and risk stratification remains unclear. This study aims to evaluate the association between PSMA PET/CT characteristics and biochemical recurrence-free survival (BRFS) after robot-assisted radical prostatectomy (RARP) in patients with prostate cancer. METHODS: In this international multicentre retrospective study, we analyzed 476 patients with localized or locally advanced miN0 prostate cancer, staged with PSMA PET/CT and MRI before RARP (2016–2023). Predictors of BRFS were identified using univariate and multivariate Cox regression with backward elimination based on Akaike information criterion (AIC). Kaplan-Meier analysis assessed the association of clinical stage by MRI, PSMA PET, and their combination with BRFS. RESULTS: In total 476 patients were included with a median follow-up of 18.0 months (IQR 6.9–29.3). Of the 127 BCRs, 101 (79.5%) occurred within two years post-surgery. The final multivariate model included initial PSA (10–20 vs. <10: HR 1.92 [95% CI 1.21–3.05]; >20 vs. <10: HR 2.26 [95% CI 1.30–3.93]), biopsy ISUP grade group (2–3 vs. 1: HR 2.28 [95% CI 0.70–7.41]; 4–5 vs. 1: HR 3.62 [95% CI 1.12–11.65]), MRI T-stage (T3a vs. ≤T2: HR 1.19 [95% CI 0.75–1.90]; ≥T3b vs. ≤T2: HR 2.09 [95% CI 1.21–3.62]), and PSMA PET T-stage (T3a vs. ≤T2: HR 1.05 [95% CI 0.59–1.85]; ≥T3b vs. ≤T2: HR 2.75 [95% CI 1.63–4.63]). From the full model, clinical T-stage, MRI-derived index diameter, SUVmax, PSMAtotal and PSMAvol were eliminated. The 2-year BRFS was 19% (95% CI 6.7–51%) in patients with T3b disease on both MRI and PSMA PET compared to 58% (95% CI 40–84%) in those with T3b detected only on MRI (p = 0.03). CONCLUSION: Clinical tumor stage assessed by PSMA PET was independently associated with BRFS in multivariate analysis, adjusting for clinical parameters and MRI-derived staging. This suggests that incorporating PSMA PET-based local staging may improve risk stratification and guide treatment decisions.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sweere V, Slot AB, Hermsen R, et al. Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2025. PMID: 40717186. doi:10.1007/s00259-025-07455-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。